December 2002
From Society of Nuclear Medicine
Society of Nuclear Medicine hosts Mid-Winter Educational Meeting The Society of Nuclear Medicine will open its annual Mid-Winter Educational Symposium on January 25--26, 2003, at the Westin Diplomat Resort in Hollywood, Florida. The symposium will host nuclear medicine physicians, radiologists, cardiologists, oncologists, neurologists, technologists, scientists, pharmacists, industry leaders, and members of the press involved and interested in current and emerging technical and clinical applications of nuclear medicine. A faculty of noted physicians, scientists, and technologists will provide expert insight on the rapidly emerging field of molecular imaging and the advancing role of nuclear medicine in diagnosis and therapy.Ten in-depth symposia will be presented, each of which offers continuing education credits. Of special interest this year is a strong emphasis on the expanding base of scientific knowledge needed in current nuclear medicine practice and on those emerging technologies that promise to provide extraordinary advances in treatment and patient care. Among the highlights of the meeting will be:
- A full-day program on cardiovascular imaging. (January 25) Long used in imaging of the heart, nuclear medicine today provides targeted, noninvasive molecular imaging of the cardiovascular system. These sessions will look at state-of-the-art technologies, novel radiotracers, and controversial issues in cardiac imaging.
- A full-day program on positron emission tomography (PET)/dual modality imaging. (January 26). The applications of PET in functional imaging are expanding rapidly. This session will provide an overview of radiopharmaceuticals, new uses of PET in combination with other modalities, and promising directions for future research.
- A full-day program for radiologic technologists. (January 25) Designed by technologists for technologists, this program will survey new therapeutic applications and novel imaging technologies.
- Presentations on emerging applications in radioimmunotherapy. (January 25 and 26) The latest developments in this breakthrough field that images and treats cancer with radiolabeled monoclonal antibodies will be discussed. Special attention will be given to results of treatment in non-Hodgkin's lymphoma, for which the first FDA-approved radioimmunotherapy is now in clinical use.
Additional information on the meeting, as well as important dates for registration is available at the SNM Web site at www.snm.org. The Society of Nuclear Medicine is an international scientific and professional organization of more than 14,000 members dedicated to promoting the science, technology, and practical applications of nuclear medicine. The SNM is based in Reston, VA. | |